Phenylketonuria - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

GervanoRA's pipeline analysis and opportunity assessment report "Phenylketonuria Pipeline Drugs - Opportunity Assessments, Market Dynamics and Pipeline Analytics H2 2020" analyzed and assessed Phenylketonuria (PKU) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Phenylketonuria drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Phenylketonuria area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Phenylketonuria drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of Phenylketonuria.

Our comprehensive analysis on the Phenylketonuria drug pipeline identified twenty-one (21) drug candidates undergoing different stages of development- from Early R&D to Phase 2 stage. Among these, five drug candidates are in clinical stages of development and a total of sixteen molecules are in non-clinical stage of development. The drug pipeline consists of thirteen preclinical drug candidates and three still in their early stages of discovery.

The report has covered a total of nineteen (19) companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 12 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• ⚫ Unmet needs and Opportunities
• ⚫Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• ⚫ Patent Analytics of Pipeline Molecules
• ⚫ Pipeline Analysis of all Drug Molecules and Estimated Pipeline Drug Approval Time lines of all Clinical Stage Pipeline Drug Candidates
• ⚫ Clinical Stage and Preclinical Stage Drug Descriptions along with Development Milestones
• ⚫ Opportunity Assessments through Competitive Benchmarking
• ⚫ Evaluate Current and Future Competitive Landscape through Company Profiles
• ⚫ Key Established Company Profiles with SWOT Analysis
• ⚫ Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.